NPR Features HemoShear's Transformational Drug Discovery Approach
Tuesday, December 16, 2014
Dr. Moira Gunn, host of NPR's Tech Nation, sat down with Dr. Brian Wamhoff, co-founder and vice president of R&D at HemoShear, to discuss the importance of accurate human disease models for successful drug discovery. Dr. Wamhoff explains how HemoShear leverages its best-in-class human tissue disease models to uncover human disease biology and discover new drug treatments. "It's a whole new way of doing drug development," he says.
Dr. Wamhoff says that the current state of drug discovery and development relies heavily on traditional cell cultures and animal models that do not reliably mimic human biology, leading to erroneous conclusions and unsustainably high rates of new drug failure. HemoShear's translational tissue systems, however, restore important physiological cues to human tissue in the laboratory to recreate healthy and disease biology.
Dr. Wamhoff goes on to explain that HemoShear has recreated human fatty liver disease in the laboratory, a disease that affects 95% of patients with diabetes, for understanding the biology of the disease and accelerating discovery of new treatments. No physiologically accurate models of fatty liver disease exist today.
HemoShear has important partnerships with the National Cancer Institute working toward developing drugs for human liver cancers as well as Children’s National Health System to advance discovery of rare disease treatments.